
Emmecell has dosed the first patient in its Phase II EMERALD trial of EO2002, an investigational cell therapy for adults with corneal oedema caused by corneal endothelial dysfunction.
The multicentre, randomised, double-masked, placebo-controlled US study (NCT07729137) is assessing two EO2002 doses against placebo in patients with corneal oedema, including cases linked to Fuchs endothelial corneal dystrophy and pseudophakic bullous keratopathy.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Patients will receive a single intracameral injection containing either 150,000 or 500,000 EO2002 cells, or placebo. The study will monitor them for 52 weeks after treatment.
The trial’s primary endpoint evaluates the percentage of treated eyes that gain at least 15 letters in best-corrected visual acuity from baseline at week 26.
It will also measure average changes in visual acuity and central corneal thickness, alongside safety assessments.
Emmecell plans for EMERALD to become the first of two studies in its proposed registrational programme.
EO2002 is an allogeneic cultured human corneal endothelial cell therapy. It uses cells labelled magnetically, followed by placement of an external magnetic patch intended to direct and retain cells at the corneal endothelium.
The company is developing the approach as a single-injection treatment intended to avoid transplantation of donor corneal tissue. EO2002 has not received approval for commercial use.
Emmecell CEO Ramin Valian said: “Starting dosing in EMERALD is an important step toward evaluating a different treatment approach for patients with corneal endothelial disease. Our goal is to restore corneal function through a single injection and reduce the burden of transplant surgery.
“This randomised, placebo-controlled study is designed to generate the evidence needed to evaluate that potential and guide the next stage of EO2002’s development. We thank the patients, investigators and study teams making this work possible.”
EO2002 received the US Food and Drug Administration’s (FDA) regenerative medicine advanced therapy (RMAT) designation in July 2026.
In November 2024, Emmecell reported positive topline outcomes from a randomised Phase I extension trial of EO2002 for treating corneal oedema.
Cell & Gene therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
